Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS‐CoV‐2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL
Alessandro Campanella(Vita-Salute San Raffaele University), Paolo Ghia(Vita-Salute San Raffaele University), Massimo Massaia(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Shai Levi(Tel Aviv Sourasky Medical Center), Yair Herishanu(Tel Aviv University), Emanuela Sant’Antonio(IRCCS Ospedale San Raffaele), Quincy Hofsink(Amsterdam Neuroscience), Carlo Combi(Vita-Salute San Raffaele University), A Capasso(Vita-Salute San Raffaele University), Salem Alshemmari(Kuwait Cancer Control Center), Lydia Scarfò(IRCCS Ospedale San Raffaele), Angsurat Raya(Josep Carreras Leukaemia Research Institute), Horia Bumbea(Carol Davila University of Medicine and Pharmacy), Michela Frenquelli(Vita-Salute San Raffaele University), I. S. Nijhof(St. Antonius Ziekenhuis), Michael Doubek(Central European Institute of Technology), Κώστας Σταματόπουλος(Centre for Research and Technology Hellas), Sabine Haggenburg(Amsterdam Neuroscience), Maria Colia(IRCCS Ospedale San Raffaele), Carol Moreno(Hospital de Sant Pau), Mette D. Hazenberg(Amsterdam Neuroscience), Magdalena Kättström(Örebro University), Thomas Chatzikonstantinou(G. Papanikolaou General Hospital), Arnon P. Kater(Amsterdam University Medical Centers), Jana Kotašková(Central European Institute of Technology), Filip Vrbacký(Charles University), Silvia Heltai(IRCCS Ospedale San Raffaele), Joanna Zaleska(Medical University of Lublin), Niki Stavroyianni(G. Papanikolaou General Hospital), Elisabetta Albi(University of Perugia), Martin Šimkovič(Charles University), Viviana Roman(Institute of Virology of the Slovak Academy of Sciences), Maria Karypidou(Centre for Research and Technology Hellas), Pamela Ranghetti(IRCCS Ospedale San Raffaele), Krzysztof Giannopoulos(Medical University of Lublin), E. Perotta(Vita-Salute San Raffaele University), Caterina Taccetti(Vita-Salute San Raffaele University), Davide Bisogno(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Ignazio Ezio Tripoli(Department of Medical Sciences), Massimo Locatelli, V. M. Popov(Spitalul Clinic Colentina), Eloise Scarano(IRCCS Ospedale San Raffaele), F. Martini(Vita-Salute San Raffaele University), Christos Demosthenous(G. Papanikolaou General Hospital)
Cited by 15
Related Papers
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907